Eli Lilly’s lucrative Q1 2022 driven by Trulicity and COVID-19 antibodiesAlzheimer’s disease, Bamlanivimab (LY-CoV555), Bebtelovimab (LY-CoV1404; LY3853113), Business, COVID-19 Antibodies, Diabetes, Diabetes drugs, Earnings per share (EPS), Eli Lilly, Etesevimab (Lilly), Financials, Forecasts, Obesity, Obesity, Sales, Therapeutics, TrulicityEli Lilly had a lucrative first-quarter 2022, with revenue growth rising 15 percent driven by sales of the company’s diabetes drug Trulicity and its COVID-19 antibodies. Read more April 28, 2022/by BioSpace https://www.pharmalive.com/wp-content/uploads/2022/04/BioSpaceLillyResearchLaboratories.jpg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2022-04-28 07:09:372022-04-28 12:15:46Eli Lilly’s lucrative Q1 2022 driven by Trulicity and COVID-19 antibodies